AstraZeneca PLC's commercial teams are all set for the US launch of anifrolumab, the first medicine to be approved in over a decade for lupus, at the end of August, the company's biopharmaceuticals head has told Scrip.
Ruud Dobber said that the US Food and Drug Administration's approval of anifrolumab, which has the brand name Saphnelo, for...